by | Sep 28, 2023 | Publications
Ir J Med Sci. 2023 Sep 28. doi: 10.1007/s11845-023-03535-y. Online ahead of print. ABSTRACT OBJECTIVES: The aim of this study was to retrospectively evaluate the effect of plasmapheresis treatment concomitant with chemotherapy and the number of sessions on renal...
by | Sep 28, 2023 | Publications
Cancers (Basel). 2023 Sep 13;15(18):4533. doi: 10.3390/cancers15184533. ABSTRACT Multiple myeloma (MM) is an incurable malignancy of plasma cells and the second most common hematologic malignancy in the United States. Although antibodies in clinical cancer therapy are...
by | Sep 28, 2023 | Publications
Cancers (Basel). 2023 Sep 21;15(18):4667. doi: 10.3390/cancers15184667. ABSTRACT Renal function impairment (RI) is a common complication in multiple myeloma (MM). However, limited data exist on the safety and efficacy of anti-MM regimens in patients with severe RI, as...
by | Sep 28, 2023 | Publications
Int J Mol Sci. 2023 Sep 14;24(18):14097. doi: 10.3390/ijms241814097. ABSTRACT Lenalidomide, a well-established drug for the treatment of multiple myeloma, significantly enhances patients’ survival. Previous clinical studies have demonstrated that its main side...
by | Sep 28, 2023 | Publications
Life (Basel). 2023 Aug 31;13(9):1841. doi: 10.3390/life13091841. ABSTRACT Anti-CD38 monoclonal antibody (MoAB) therapy has significantly improved the prognosis of patients with multiple myeloma. However, not all patients sustain durable responses. We aimed to describe...
by | Sep 28, 2023 | Publications
J Patient Exp. 2023 Sep 25;10:23743735231202733. doi: 10.1177/23743735231202733. eCollection 2023. ABSTRACT A qualitative study of the experiences of patients who received autologous stem cell transplant (ASCT) for the treatment of multiple myeloma (MM) was conducted...
